 DALLAS, April 22, 2022 PRNewswire -- Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. and machine learning ML platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close. 